Abbott Meridia sNDA Extends Use of Obesity Agent From One Year To Two
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labeling for Abbott’s obesity agent Meridia (sibutramine) has added two-year maintenance data, following approval of a supplemental NDA Feb. 16. The approval gives the drug data on length of treatment equal to that in labeling for Roche’s competing agent Xenical (orlistat).